NICE issues Appraisal Consultation Document on pemetrexed for the maintenance treatment of non-small-cell lung cancer

Source: NICE Area: News NICE has issued new draft guidance not recommending pemetrexed (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin. NICE has already recommended pemetrexed as a first line treatment option for NSCLC and as a maintenance treatment option following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. This appraisal is concerned with the extension to the marketing authorisation for pemetrexed as a maintenance treatment following pemetrexed and cisplatin.   The committee noted that the results from the PARAMOUNT clinical trial indicated that pemetrexed provides a gain in progression-free survival (1.28 months) and overall survival (2.85 months). However, the most plausible incremental cost-effectiveness ratio (ICER) was in excess of £76,300 per Quality Adjusted Life Year (QALY) gained (which is higher than that normally considered to be cost-effective). The ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news